MARKET

IMMP

IMMP

Immutep
NASDAQ
0.4859
+0.0056
+1.17%
After Hours: 0.4821 -0.0038 -0.78% 19:20 05/22 EDT
OPEN
0.4890
PREV CLOSE
0.4803
HIGH
0.4941
LOW
0.4800
VOLUME
363.19K
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
0.2928
MARKET CAP
71.61M
P/E (TTM)
-1.2713
1D
5D
1M
3M
1Y
5Y
1D
Immutep reports Q1 adjusted EPS 61c vs 34c last year
TipRanks · 19h ago
Immutep Hit With Securities Suit After TACTI-004 Trial Halt and 83% Stock Drop 
TipRanks · 1d ago
Immutep executives face securities class action after ADRs plunge 83% on trial collapse
PUBT · 1d ago
IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
PR Newswire · 2d ago
Weekly Report: what happened at IMMP last week (0511-0515)?
Weekly Report · 5d ago
Immutep Faces Securities Lawsuit After 83% Stock Collapse Following Phase III Trial Discontinuation 
TipRanks · 05/15 18:38
IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline
PR Newswire · 05/13 13:00
IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action – Contact Levi & Korsinsky
TipRanks · 05/13 04:15
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.